{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:41:38Z","timestamp":1776163298684,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201494"],"award-info":[{"award-number":["82201494"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2022YFS0315"],"award-info":[{"award-number":["2022YFS0315"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["21HXFH041"],"award-info":[{"award-number":["21HXFH041"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2021YFS0173"],"award-info":[{"award-number":["2021YFS0173"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2022NSFSC1432"],"award-info":[{"award-number":["2022NSFSC1432"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jneuroim.2023.578151","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T11:27:15Z","timestamp":1689074835000},"page":"578151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"382","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Ren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling Yao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen Qin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2023.578151_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000448286","article-title":"Multiple autoantibodies and neuromyelitis optica spectrum disorders","volume":"23","author":"Chen","year":"2016","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.jneuroim.2023.578151_bb0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577494","article-title":"Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders","volume":"353","author":"Du","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1865","article-title":"Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Fan","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13760-019-01176-6","article-title":"Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders","volume":"120","author":"Gkaniatsou","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104023","article-title":"The description of neuromyelitis optica spectrum disorder: patient registry in Yangtze River Delta area of China","volume":"66","author":"Huang","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jneuroim.2023.578151_bb0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","article-title":"Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen","volume":"291","author":"Jarius","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0045","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.11.012","article-title":"The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder","volume":"328","author":"Lee","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0060","article-title":"Analysis of predictive risk factors in Aquaporin-4-IgG positive highly active Neuromyelitis Optica Spectrum disorders","volume":"12","author":"Li","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0065","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ene.12714","article-title":"Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica","volume":"23","author":"Masuda","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0070","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2023.578151_bb0075","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/neu.2016.49","article-title":"Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica","volume":"29","author":"Pereira","year":"2017","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.jneuroim.2023.578151_bb0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrrheum.2017.74","article-title":"Antinuclear antibody testing - misunderstood or misbegotten?","volume":"13","author":"Pisetsky","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0090","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jneuroim.2023.578151_bb0095","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"267","author":"Shi","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0065-2776(08)60641-0","article-title":"Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology","volume":"44","author":"Tan","year":"1989","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12803","article-title":"Anti-centrosome antibodies: prevalence and disease association in Chinese population","volume":"90","author":"Wang","year":"2019","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2023.578151_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000358218","article-title":"Combined screening for serum anti-nuclear and anti-aquaporin-4 antibodies improves diagnostic accuracy for distinguishing neuromyelitis optica from multiple sclerosis","volume":"72","author":"Wu","year":"2014","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2023.578151_bb0120","article-title":"Dense fine speckled immunofluorescence pattern in a Chinese population: prevalence and clinical association","volume":"36","author":"Zhang","year":"2022","journal-title":"J. Clin. Lab. Anal."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572823001376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572823001376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:42:19Z","timestamp":1759048939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572823001376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"alternative-id":["S0165572823001376"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578151","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578151"}}